摘要
目的探讨应用华法林联合参松养心胶囊治疗心房颤动(AF)的临床效果及对病人血清基质金属蛋白酶2(MMP-2)和高敏C反应蛋白(hs-CRP)水平的影响。方法选取西安市长安医院2015年1月—2016年12月收治的150例AF病人,采用随机数字表法均分为对照组和观察组。对照组给予华法林治疗,观察组在此基础上加用参松养心胶囊治疗。分析比较两组临床疗效,治疗前后房颤发作情况,血清MMP-2、hs-CRP水平及不良反应。结果治疗12周后,观察组临床疗效总有效率高于对照组(P<0.05)。治疗后两组发作频率及持续时间均较治疗前显著降低或缩短(P<0.01);观察组改善效果更显著(P<0.01)。与治疗前相比,两组治疗12周后MMP-2、hs-CRP水平均显著降低(P<0.01);观察组改善效果更显著(P<0.01)。两组均未见明显不良反应/事件。结论应用华法林联合参松养心胶囊治疗AF能有效减轻或消除病人症状,改善病情,疗效显著且安全性较高。
Objective To investigate the clinical effect of warfarin and Shensong Yangxin capsule （SYC） in the treatment of atrial fibril-lation （AF） and its effect on serum levels of matrix metalloproteinase 2 （MMP 2） and high sensitive C reactive protein （hs CRP） in patients.Methods One hundred and fifty patients with AF treated in our hospital from January 2015 to December 2016 were select-ed,and randomly divided into two groups： control group treated with warfarin,and observation group treated with warfarin and SYC. The clinical efficacy and the incidence of atrial fibrillation before and after treatment,the levels of serum MMP 2,hs CRP and ad-verse reactions were observed.Results After the treatment of 12 weeks,the total effective rate in observation group was higher than that in control group （P 〈 0.05）.After treatment,the seizure frequency and duration in two groups were significantly lower than those before treatment （P 〈0.01）,which was better in observation group than that in control group （P 〈0.01）.Compared with those before treatment, the levels of MMP 2 and hs CRP were significantly decreased in two groups after the treatment of 12 weeks （ P 〈 0.01）, which was better in observation group than that in control group （P 〈 0.01）.There was no obvious adverse reactions in two groups. Conclusion Warfarin and SYC can effectively reduce or eliminate the symptoms and improve the disease in patients with AF.The curative effect is significant and safe.
出处
《中西医结合心脑血管病杂志》
2017年第17期2101-2103,共3页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词
心房颤动
参松养心胶囊
华法林
高敏C反应蛋白
基质金属蛋白酶2
atrial fibrillation
Shensong Yangxin capsule
warfarin
high sensitive C-reactive protein
matrix metalloproteinase 2
作者简介
通讯作者：党亚东,E-mail：yanjun8404@163.com
